Acne Vulgaris Market Summary

• The Acne vulgaris Market Size is anticipated to grow with a significant CAGR during the study period (2022-2036).
• The leading Acne vulgaris companies developing therapies in the market include - Ascletis Pharma, Sagimet Biosciences, Sun Pharmaceutical Industries, Bausch Health, Ortho Dermatologics, and others.

Acne vulgaris Market & Epidemiology Insights

• Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit characterized by the development of comedones, papules, pustules, nodules, and, in severe cases, permanent scarring. The disease results from a multifactorial interplay among increased sebum production, follicular hyperkeratinization, proliferation of Cutibacterium acnes, and cutaneous inflammation.
• Acne vulgaris is one of the most prevalent dermatological disorders worldwide, affecting approximately 85% of adolescents and young adults, although it may persist into or first present during adulthood. Disease prevalence and severity vary across age groups, sex, and geographic regions.
• According to a secondary analysis of a epidemiological studies, acne vulgaris affects individuals across all age groups in the US, with 65.2% of treated cases occurring in females, 36.5% in adolescents aged 12–17 years, and 61.9% in adults aged =18 years. The authors noted that these estimates likely underestimate the true population burden because the analysis included only treated cases.
• Clascoterone (WINLEVI) and clindamycin phosphate/adapalene/benzoyl peroxide (CABTREO) represent important recent additions to the acne vulgaris treatment landscape. WINLEVI is the first topical androgen receptor inhibitor for acne, while CABTREO is the first fixed-dose triple-combination topical therapy, reflecting continued innovation aimed at targeting multiple pathogenic pathways of the disease.
• Despite advances in available therapies, significant unmet needs remain, particularly among patients with moderate-to-severe, truncal, recurrent, or treatment-resistant acne and those at risk of permanent scarring. There remains a need for therapies that provide rapid, durable lesion clearance, minimize antibiotic exposure, improve tolerability, and address the underlying inflammatory and hormonal drivers of disease.
• The acne vulgaris market is expected to experience steady growth during the forecast period (2026–2036), driven by the high disease burden, increasing recognition of its long-term physical and psychosocial impact, earlier diagnosis, expanding access to dermatological care, and advances in understanding the inflammatory, hormonal, and microbiome-related mechanisms underlying disease heterogeneity. Continued innovation, including the clinical development of emerging therapies such as denifanstat (ASC40), is expected to expand treatment options, promote more personalized management, intensify market competition, and further reshape the acne vulgaris treatment landscape.

Request for unlocking the sample page of the "Acne Vulgaris Market Forecast"

Key Factors Driving the Acne Vulgaris Market Landscape:

• Rising Prevalence of Acne Vulgaris: The increasing incidence of acne among adolescents and adults, driven by hormonal changes, lifestyle factors, and environmental influences, continues to expand the patient pool and fuel market growth.
• Advancements in Acne Therapies: The introduction of novel topical formulations, oral therapies, combination treatments, biologics, and investigational drugs is improving treatment outcomes and driving demand for innovative acne management solutions.
• Growing Awareness and Early Diagnosis: Greater public awareness of skin health, increased access to dermatologists, and the influence of digital health platforms have encouraged earlier diagnosis and timely treatment of acne vulgaris.
• Increasing Demand for Personalized and Prescription Treatments: Patients are increasingly seeking customized treatment regimens based on acne severity and skin type, boosting the adoption of prescription medications and dermatologist-guided therapies.
• Strong Research and Commercial Investments: Pharmaceutical companies are investing heavily in clinical research, product development, and strategic collaborations to expand their acne treatment portfolios, contributing to a competitive and evolving market landscape.

DelveInsight’s comprehensive report titled "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2036" offers a detailed analysis of acne vulgaris across key epidemiological segments, including severity-specific, gender-specific, and age-specific patient populations. It presents historical and forecasted epidemiological data on prevalent cases, diagnosed prevalent cases, and treated patient populations across the 7MM. The report also evaluates the burden of major clinical manifestations and complications, including comedonal, inflammatory, and nodulocystic lesions, post-inflammatory hyperpigmentation, acne scarring, and associated psychosocial comorbidities such as anxiety, depression, and reduced quality of life, all of which contribute significantly to disease burden and healthcare utilization. In addition to epidemiology, the report provides comprehensive insights into patient demographics, disease burden, treatment practices, and other market-related factors influencing the acne vulgaris landscape. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2026 to 2036.

The report analyzes the existing treatment practices and unmet medical requirements in acne vulgaris. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Acne Vulgaris Disease Understanding

Acne Vulgaris Overview and Diagnosis

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit characterized by the development of comedones, papules, pustules, nodules, and, in severe cases, cysts and permanent scarring. The disease results from a complex interplay among increased sebum production, follicular hyperkeratinization, proliferation of Cutibacterium acnes, and inflammatory responses, with genetic, hormonal, environmental, and lifestyle factors contributing to disease susceptibility and severity. Acne vulgaris encompasses several clinical forms, ranging from predominantly comedonal and inflammatory acne to nodulocystic disease, resulting in considerable heterogeneity in clinical presentation, disease severity, and long-term outcomes.

The diagnosis of acne vulgaris is primarily based on clinical evaluation, including lesion morphology, anatomical distribution, and disease severity assessment. Diagnostic evaluation may incorporate validated grading systems to classify disease severity and monitor treatment response, while laboratory investigations are generally reserved for patients with suspected underlying endocrine disorders or atypical clinical presentations. Advances in understanding the molecular, hormonal, and microbiome-related mechanisms underlying acne have improved disease characterization and patient stratification. Given the potential for permanent scarring and substantial psychosocial burden, early diagnosis and accurate severity assessment remain essential for optimizing long-term outcomes and reducing disease burden.

Further details related to country-based variations are provided in the report...

Current Acne Vulgaris Treatment Landscape

According to current clinical practice, the management of acne vulgaris is aimed at reducing lesion burden, preventing permanent scarring, minimizing relapse, and improving patients' quality of life. Treatment is individualized according to disease severity, lesion type, anatomical involvement, and patient-specific factors. Commonly used therapies include topical retinoids, benzoyl peroxide, topical and oral antibiotics, hormonal therapies, and oral isotretinoin for severe or refractory disease. Among recently approved targeted therapies, clascoterone (WINLEVI), the first topical androgen receptor inhibitor, and clindamycin phosphate/adapalene/benzoyl peroxide (CABTREO), the first fixed-dose triple-combination topical therapy, have expanded treatment options by targeting multiple pathogenic mechanisms involved in acne development.

Patients with moderate-to-severe, nodulocystic, truncal, or recurrent acne often require prolonged treatment and careful follow-up because of the increased risk of permanent scarring and psychosocial sequelae. Despite the availability of numerous therapeutic options, many patients continue to experience inadequate treatment response, relapse, antibiotic resistance, treatment-related adverse effects, or poor adherence. Consequently, significant unmet needs remain for therapies that provide rapid, durable disease control, reduce antibiotic dependence, improve tolerability, and address the underlying inflammatory, hormonal, and microbiome-related drivers of acne vulgaris.

Further details related to country-based variations are provided in the report…

Acne Vulgaris Epidemiology

The Acne Vulgaris epidemiology section of the acne vulgaris market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The patient pool, their trends, and the underlying assumptions are all included in this section of the report. This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of acne vulgaris. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings in the Acne Vulgaris Epidemiology Report

• According to secondary research, the diagnosed prevalence of acne among adolescents and young people in the UK reached 14.6% by 2021, representing a 7.4% increase compared with 1990. When self-managed cases are also considered, acne is estimated to affect up to 95% of adolescents, highlighting the substantial underrecognition of the true disease burden.
• Based on literary search, a Japan-based epidemiological study, 58.6% of students were affected by acne vulgaris, with a mean age of onset of 13.3 years, indicating that the disease commonly develops during early adolescence.
• Major factors contributing to regional differences in the prevalence and burden of acne vulgaris across the 7MM include variations in genetic predisposition, hormonal and environmental influences, diagnostic practices, and disease awareness. The epidemiology of acne vulgaris is expected to evolve during the forecast period (2026–2036), driven by increasing awareness, earlier diagnosis, improved disease characterization, and growing recognition of acne across adolescent and adult populations.

Acne Vulgaris Epidemiology Segmentation

• Total Prevalent Cases of Acne Vulgaris
• Total Diagnosed Prevalent Cases of Acne Vulgaris
• Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris
• Age-specific Diagnosed Prevalent Cases of Acne Vulgaris
• Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris
• Total Treated Cases of Acne Vulgaris

Further details related to country-based variations are provided in the report…

Acne Vulgaris Market Outlook

The acne vulgaris therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2026–2036).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the acne vulgaris market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Acne Vulgaris Drug Analysis & Competitive Landscape

The acne vulgaris drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III Acne Vulgaris clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the acne vulgaris treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the acne vulgaris therapeutics market.

Approved Therapies for Acne Vulgaris

Clascoterone (WINLEVI): Sun Pharmaceutical Industries

Clascoterone (WINLEVI) is an FDA-approved topical androgen receptor inhibitor indicated for the treatment of acne vulgaris in patients aged 12 years and older. By locally inhibiting androgen receptor signaling within the pilosebaceous unit, it reduces sebum production and inflammation while minimizing systemic exposure. As the first topical therapy with this novel mechanism of action, WINLEVI offers a targeted, non-antibiotic treatment option for acne vulgaris.

• In October 2025, the European Commission approved WINLEVI for the topical treatment of acne vulgaris in patients aged 12 years and older, marking the product's first approval in the European Union.
• In August 2020, the US FDA approved Sun Pharmaceutical Industries' WINLEVI for the topical treatment of acne vulgaris in patients aged 12 years and older.

Clindamycin phosphate, adapalene, and benzoyl peroxide (CABTREO): Bausch Health/ Ortho Dermatologics

Clindamycin phosphate, adapalene, and benzoyl peroxide (CABTREO) is an FDA-approved fixed-dose topical triple-combination therapy indicated for the treatment of acne vulgaris in patients aged 12 years and older. By combining an antibiotic, a retinoid, and benzoyl peroxide, CABTREO targets multiple pathogenic mechanisms of acne, including bacterial proliferation, inflammation, and abnormal follicular keratinization. As the first FDA-approved triple-combination topical therapy, it offers a convenient once-daily treatment option for acne vulgaris.

Long-term data published in January 2026 demonstrated that CABTREO maintained sustained efficacy and was generally well tolerated over six months of treatment, supporting its use as a once-daily triple-combination topical therapy for acne vulgaris.

In October 2023, the US FDA approved Bausch Health's CABTREO topical gel for the treatment of acne vulgaris in patients aged 12 years and older. CABTREO is the first FDA-approved fixed-dose triple-combination topical therapy for acne vulgaris.

Note: Detailed marketed therapies assessment will be provided in the final report…

Acne Vulgaris Pipeline Analysis

The acne vulgaris market is expected to evolve gradually, driven by a growing number of emerging therapies currently in clinical development. Key players such as Ascletis Pharma / Sagimet Biosciences’s Denifanstat (ASC40), among others, are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this allergic condition.

Denifanstat (ASC40): Ascletis Pharma / Sagimet Biosciences

Denifanstat (ASC40) is an investigational oral fatty acid synthase (FASN) inhibitor being developed by Ascletis Pharma and Sagimet Biosciences for the treatment of acne vulgaris. By inhibiting de novo fatty acid synthesis, it reduces sebum production and inflammation, targeting key pathogenic mechanisms underlying acne. Clinical studies have demonstrated significant reductions in inflammatory lesion counts with a favorable safety profile, supporting its potential as a novel systemic therapy for moderate-to-severe acne vulgaris.

• In April 2026, Sagimet Biosciences reported plans to initiate a US Phase III trial of denifanstat for moderate-to-severe acne in 2H 2026 following regulatory consultations.

Note: Detailed emerging therapies assessment will be provided in the final report…

Acne Vulgaris Market Segmentation

DelveInsight's 'Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a detailed outlook of the current and future acne vulgaris market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Acne Vulgaris Market Size by Countries

The acne vulgaris market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the United States held a significant share of the overall 7MM (Seven Major Markets) acne vulgaris market, primarily attributed to the country's higher diagnosed prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Acne Vulgaris Market Size by Therapies

Acne Vulgaris Market Size by Therapies is categorized into current and emerging markets for the study period 2022–2036.

Note: Detailed market segment assessment will be provided in the final report...

Acne Vulgaris Drugs Uptake

This section focuses on the sales uptake of potential of acne vulgaris drugs that have recently been launched or are anticipated to be launched in the acne vulgaris market between 2022 and 2036. It estimates the market penetration of acne vulgaris drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the acne vulgaris market.

The emerging acne vulgaris therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the acne vulgaris market.

Acne Vulgaris Pipeline Development Activities

The Acne Vulgaris pipeline report offers an analysis of Acne Vulgaris clinical trials within  Phase I/II and III stages and examines companies involved in developing targeted therapeutics for acne vulgaris. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Acne Vulgaris clinical Trial Activities

The Acne Vulgaris clinical trials analysis report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging acne vulgaris therapies.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Acne Vulgaris...

Acne Vulgaris Market Access and Reimbursement

DelveInsight’s ‘Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a descriptive overview of the market access and reimbursement scenario of acne vulgaris.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views on Acne Vulgaris Report

To keep up with current acne vulgaris market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in acne vulgaris domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or acne vulgaris market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the acne vulgaris unmet needs.

Acne Vulgaris: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as National Jewish Health, Charité – Universitätsmedizin Berlin, Hospital Clínic de Barcelona, Humanitas Research Hospital, Hôpital Européen Georges-Pompidou, Royal Brompton Hospital, and Jikei University Hospital among others.

Note: Detailed assessment of KOL Views will be provided in the full report on Acne Vulgaris.

Acne Vulgaris Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the acne vulgaris market, utilizing various competitive intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Acne Vulgaris Market Report Insights

• Acne Vulgaris Patient Population
• Acne Vulgaris Therapeutic Approaches
• Acne Vulgaris Pipeline Analysis
• Acne Vulgaris Market Size and Trends
• Acne Vulgaris Market Opportunities
• Impact of Upcoming Acne Vulgaris Therapies

Acne Vulgaris Market Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Acne Vulgaris Epidemiology Segmentation
• Competitive Landscape
• Highly Analyzed Acne Vulgaris Market
• Acne Vulgaris Drugs Uptake

Acne Vulgaris Market Report Assessment

• Acne Vulgaris Current Treatment Practices
• Acne Vulgaris Unmet Needs
• Acne Vulgaris Pipeline Product Profiles
• Acne Vulgaris Market Attractiveness
• Acne Vulgaris Market Drivers
• Acne Vulgaris Market Barriers

Key Questions Answered In The Acne Vulgaris Market Report:

• How common is acne vulgaris?
• What are the key findings of acne vulgaris epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022–2036)?
• What are the currently available treatments for acne vulgaris?
• What are the disease risk, burden, and unmet needs of acne vulgaris?
• At what CAGR is the acne vulgaris market and its epidemiology is expected to grow in the 7MM during the forecast period (2026–2036)?
• How would the unmet needs impact the acne vulgaris market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of acne vulgaris in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of Acne Vulgaris patients during the forecast period (2026–2036)?
• How many companies are currently developing therapies for the treatment of acne vulgaris?

Reasons to buy Acne Vulgaris Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the acne vulgaris market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1.           What are the treatment goals for acne vulgaris?

The primary goals in the treatment of acne vulgaris are to reduce inflammatory and non-inflammatory lesions, prevent permanent scarring, minimize relapse, and improve patient quality of life. Treatment strategies target the key pathogenic mechanisms of acne, including excess sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and inflammation. Therapeutic approaches may include topical retinoids, benzoyl peroxide, antibiotics, hormonal therapies, oral isotretinoin, and recently approved targeted topical therapies such as Clascoterone (WINLEVI) and clindamycin phosphate/adapalene/benzoyl peroxide (CABTREO), alongside emerging agents with novel mechanisms of action.

2.           What are the challenges in managing acne vulgaris?

Managing acne vulgaris remains challenging due to its heterogeneous clinical presentation, variability in disease severity, and differences in treatment response across patient populations. Despite the availability of multiple therapeutic options, many patients continue to experience persistent or recurrent lesions, acne scarring, and significant psychosocial burden. Additional challenges include antibiotic resistance, treatment-related adverse effects, poor adherence to prolonged treatment regimens, and limited options for patients with moderate-to-severe or treatment-resistant disease. Furthermore, achieving durable disease control while minimizing relapse and preventing permanent scarring remains a significant unmet need in acne vulgaris.

3.           What are the key factors driving the growth of the acne vulgaris market?

The acne vulgaris market is being driven by its high and growing disease burden, increasing awareness, improved diagnosis, and rising demand for effective therapies that provide durable disease control with favorable safety profiles. Advances in understanding the roles of androgen signaling, inflammation, and the skin microbiome are supporting the development of novel targeted therapies. Additionally, growing concerns regarding antibiotic resistance, expanding treatment options, and increasing clinical research activity are expected to contribute to continued market expansion during the forecast period.

4.           How will the acne vulgaris market and epidemiology forecast report benefit the clients?

The report provides comprehensive insights into the acne vulgaris market, including epidemiological trends across the 7MM, current treatment practices, approved and emerging therapies, competitive dynamics, regulatory developments, and key unmet needs. These insights support strategic decision-making, business development, market opportunity assessment, competitive benchmarking, and commercialization planning for stakeholders operating across the dermatology, skincare, biotechnology, and pharmaceutical sectors.